showed a 27% reduction in the risk of death versus placebo AstraZeneca's Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited ...

Patients on anifrolumab spent more time in remission and low disease activity, and reached those states more quickly, vs. placebo. Achieving these states can stave off permanent organ damage.